Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lynn

Showing results (201-210 of 240) with videos related to

Pageof 24
Sort By:
Clinical Breast Cancer|July 26, 2025
Hidden Costs of Endocrine Therapy for Black Breast Cancer Survivors: A Qualitative Examination of Patient and Provider ExperiencesKimberley T Lee, Carley Geiss, Hayden J Fulton, et al.
Physiological Genomics|August 21, 2016
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumorsDaniel L Hertz, N Lynn Henry, Kelley M Kidwell, et al.
Breast Cancer Research and Treatment|June 8, 2015
Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancerMegan E V Caram, Cui Guo, Monika Leja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2022
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline UpdateFabrice Andre, Nofisat Ismaila, Kimberly H Allison, et al.
Journal of the National Cancer Institute|January 24, 2018
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)Dawn L Hershman, Joseph M Unger, Katherine D Crew, et al.
British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.
Breast (Edinburgh, Scotland)|March 21, 2020
Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot studyTeresa M Salgado, Jin Liu, Holly L Reed, et al.
Breast Cancer Research and Treatment|April 3, 2013
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancerN Lynn Henry, Todd C Skaar, Jessica Dantzer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, William E Barlow, et al.
JNCI Cancer Spectrum|April 2, 2025
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trialHanna Bandos, Sungjin Kim, N Lynn Henry, et al.
Pageof 24

Showing results (201-210 of 240) with videos related to

Sort By:
Pageof 24
Clinical Breast Cancer|July 26, 2025
Hidden Costs of Endocrine Therapy for Black Breast Cancer Survivors: A Qualitative Examination of Patient and Provider ExperiencesKimberley T Lee, Carley Geiss, Hayden J Fulton, et al.
Physiological Genomics|August 21, 2016
ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumorsDaniel L Hertz, N Lynn Henry, Kelley M Kidwell, et al.
Breast Cancer Research and Treatment|June 8, 2015
Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancerMegan E V Caram, Cui Guo, Monika Leja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2022
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline UpdateFabrice Andre, Nofisat Ismaila, Kimberly H Allison, et al.
Journal of the National Cancer Institute|January 24, 2018
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)Dawn L Hershman, Joseph M Unger, Katherine D Crew, et al.
British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.
Breast (Edinburgh, Scotland)|March 21, 2020
Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot studyTeresa M Salgado, Jin Liu, Holly L Reed, et al.
Breast Cancer Research and Treatment|April 3, 2013
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancerN Lynn Henry, Todd C Skaar, Jessica Dantzer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221Ciao-Sin Chen, Gary Zirpoli, William E Barlow, et al.
JNCI Cancer Spectrum|April 2, 2025
Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trialHanna Bandos, Sungjin Kim, N Lynn Henry, et al.
Pageof 24